MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinsonism"

  • 2019 International Congress

    Unilateral leg tremor on sitting crossed-legged position as the initial manifestation of Parkinson’s disease

    I. Park, W. Yoon (Seoul, Republic of Korea)

    Objective: Our aim is to report an unusual case of initial manifestation of Parkinson's disease, which showed unilateral leg tremor on sitting crossed-legged position on…
  • 2019 International Congress

    Prolonged-release Melatonin for Sleep Disorders in Parkinson’s Disease: A Randomized trial

    JH. Ahn, M. Kim, JK. Mun, J. Youn, S. Park, W. Jang, J. Park, E. Oh, JW. Cho, JS. Kim (Seoul, Republic of Korea)

    Objective: To evaluate the efficacy of PRM in sleep disorders of patients with PD was investigated. Background: Sleep disorders are highly prevalent in patients with…
  • 2019 International Congress

    Efficacy, Safety and Tolerability of Tavapadon in Subjects With Early Stage Parkinson’s Disease

    D. Gray, R. Riesenberg, J. Werth, Y. Zhang, M. Versavel, S. Duvvuri (Boston, MA, USA)

    Objective: To evaluate the efficacy and safety of tavapadon (formerly known as PF-06649751) in subjects with early stage Parkinson’s disease. Background: Tavapadon is a potent,…
  • 2019 International Congress

    Fatal evolution of cutaneous necrosis in a patient treated with subcutaneous apomorphine infusions

    C. Marse, J. Benoit, F. Rocher, C. Giordana (Nice, France)

    Objective: Report a case of extensive cutaneous necrosis due to apomorphine treatment with fatal outcome. Background: Subcutaneous (SC) apomorphine is used as a treatment of…
  • 2019 International Congress

    A Phase 3 study of isradipine as a disease modifying agent in patients with early Parkinson’s disease (STEADY-PD III): Final study results

    T. Simuni (Chicago, IL, USA)

    Objective: The efficacy of isradipine to slow progression of disability in de novo PD participants. Background: There remains no proven therapy to slow progression of…
  • 2019 International Congress

    Effect of pill box organizers with alarm on improvement of adherence to pharmacotherapy in patients with Parkinson’s disease: a pilot study

    I. Straka, M. Minár, M. škorvánek, M. Grofik, J. Benetin, P. Valkovič (Bratislava, Slovakia)

    Objective: To find out whether pill box organizers with alarm would improve the rate of adherence in non-adherent patients with Parkinson’s disease (PD) taking three…
  • 2019 International Congress

    The role of genetic modifiers in Parkinson’s disease-associated LRRK2-G2019S mutation

    T. Courtin, G. Ianello, H. Bertrand, S. Benromdhan, C. Tesson, C. Mhiri, JC. Corvol, S. Lesage, A. Brice (Paris, France)

    Objective: The aim of the study is to use genome-wide approach to elucidate genetic variability that influences LRRK2 G2019S penetrance in Parkinson's Disease (PD). Background:…
  • 2019 International Congress

    Hereditary and geneological aspects of Parkinson’s disease and essential tremor in people of Uzbek nationality

    R. Matmurodov, K. Khalimova (Tashkent, Uzbekistan)

    Objective: To study the genealogic features of Parkinson’s disease and essential tremor in people of Uzbek nationality. Background: Parkinson's disease (PD)  and essential tremor (ET)…
  • 2019 International Congress

    WES analysis of Parkinson’s disease patients with Cancer

    Y. Gao, G. Wang, X. Xie (Shanghai, China)

    Objective: To provide evidences for the overlapping mechanistic basis between Parkinson's disease (PD) and cancer(CA), we explored the common genomic mechanisms between the two disease.…
  • 2019 International Congress

    Texas Biorepository of Human Induced Pluripotent Stem Cells for Studying Parkinson’s Disease

    S. Wijemanne, H. Hong, G. Choudhury, J. Kim, J. Ramirez-Castaneda, A. Papanastassiou, M. Daadi (San Antonio, TX, USA)

    Objective: To develop a biorepository of human induced pluripotent stem cells for studying Parkinson’s disease(PD). Background: Genetically engineered stem cells called “induced pluripotent stem cells”…
  • « Previous Page
  • 1
  • …
  • 117
  • 118
  • 119
  • 120
  • 121
  • …
  • 388
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
    • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • Life expectancy with and without Parkinson’s disease in the general population
    • Effect of Ketone Ester Supplementation on Motor and Non-Motor symptoms in Parkinson's Disease
    • An atypical and interesting feature of Parkinson´s disease
    • Effect of marijuana on Essential Tremor: A case report
    • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
    • Patients with Essential Tremor Live Longer than their Relatives
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley